Novel methods for diagnosing benign prostatic diseases

Details Novel methods for diagnosing benign prostatic diseases Novel methods for diagnosing benign prostatic diseases

G - Physics

01

N

G01N 33/573 (2006.01) G01N 33/574 (2006.01) G01N 33/68 (2006.01)

Patent

CA 2213709

The present invention relates to novel methods for diagnosing benign prostatic diseases (BPD), such as benign prostatic hyperplasia, prostatitis, or glandular atrophy, in a male human patient without requiring a biopsy. The total prostate specific antigen (PSA) level in the blood or serum of the patient is measured. If the patient has a total PSA level of between about 2,5 ng/ml and 10.0 ng/ml, then the free PSA level in the blood or serum of the patient is measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25 %, then the patient is diagnosed as having BPD. Optionally, if the patient has a total PSA level of between 10.1 ng/ml and 20.0 ng/ml, then the free PSA level in the blood or serum of the patient can also be measured. The proportion of free PSA to total PSA is calculated. If this proportion is equal to or greater than about 25 %, then the patient is diagnosed as having BPD.

L'invention concerne de nouvelles méthodes de diagnostic sans biopsie d'affections bénignes de la prostate (BPD), telles que l'adénome prostatique, la prostatite ou l'atrophie glandulaire chez un patient humain de sexe masculin. On mesure le taux d'antigènes totaux spécifiques à la prostate (PSA) dans le sang ou le sérum du patient. Si ce dernier présente un taux de PSA totaux compris entre environ 2,5 ng/ml et 10,0 ng/ml, on mesure alors le niveau de PSA libres dans le sang ou le sérum du patient. On calcule la proportion de PSA libres par rapport à celle de PSA totaux. Si cette proportion est supérieure ou égale à environ 25 %, on considère que le patient souffre de BPD. Eventuellement, si le patient présente un taux de PSA compris entre 10,1 ng/ml et 20,0 ng/ml, on peut également mesurer le taux de PSA libres dans le sang ou le sérum du patient. On calcule la proportion de PSA libres par rapport à celle de PSA totaux. Si cette proportion est supérieure ou égale à environ 25 %, on considère que le patient souffre de BPD.

Affiliated with

Also associated with

Rating

Novel methods for diagnosing benign prostatic diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel methods for diagnosing benign prostatic diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel methods for diagnosing benign prostatic diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1526366